



Accentus Medical Wins OBN Best New UK Medtech Development Award

Oxford, 5 October 2015 ... Accentus Medical, a leading developer of advanced surface modifications and coating technologies, is delighted to announce its success in winning the **Best New UK Medtech Development Programme** in the OBN 2015 Awards.

<http://www.obn.org.uk/press-release/obn-annual-awards-2015-celebrates-uks-life-sciences-champions/>



Left to right:
Ross Sommerville, Interim CEO, OBN; Kathryn Moon, representing award sponsor, Arthur J Gallagher; Dr. Philip Agg CEO, Accentus Medical

The winners in each of twelve award categories were announced at the OBN Annual Awards Dinner on Thursday 1 October 2015, held at the Ashmolean Museum, Oxford. The event was attended by senior executives and influential players from the most innovative and dynamic biotech and medtech companies in the OBN network.

The OBN judging panel of high profile global investors commented on the elegant solution that Agluna[®] provides to the massive problem of post-operative infection, and the massive difference the technology looks set to make to the need for revision surgery. They also noted that Agluna[®] is well developed and cost effective, and that Accentus Medical is attracting increased recognition for its achievements so far.

Dr Philip Agg, CEO, said: *"We are delighted to win this prestigious OBN award in the category of Best New UK Medtech Development Programme. The award comes at a time when the company is building momentum in developing and commercialising our Agluna[®] technology within several implantable medical device sectors. We are looking forward to continuing our endeavours to bring the technology into widespread clinical use, to the benefit of patients and clinicians across global healthcare markets."*

-ends-

For further information, please contact:

Lynne Trowbridge

T: +44 (0)20 7457 2861

Email: AccentusMedical@instinctif.com

About Agluna®

Agluna® harnesses the anti-microbial properties of silver ions in preventing device related infection. The technology is an electrochemical process involving high voltage anodisation of the titanium implant in phosphoric acid, followed by incorporation of silver ions from an aqueous solution. Agluna® is protected by several patent families registered in major global territories.

About Accentus Medical

Accentus Medical is a global leader in delivery of innovative, silver-based anti-microbial surface treatments and biocompatible coatings on implantable medical devices. The company combines a long history of expertise in surface technologies, with dedicated research and development of new technologies for the medical device industry. Based at the historic Harwell Oxford campus, Accentus Medical has provided expertise in surface technologies to the orthopaedic device industry since the 1970s, serving major orthopaedic and medical device manufacturers worldwide.

The company has three principal technology platforms:

- Agluna® silver anti-microbial surface treatment for prevention and control of post-operative infection,
- Acusure® plasma spray coating for improving biocompatibility and durability of implants,
- Acusure Ag® plasma spray coating incorporating antimicrobial silver ions

These technologies are supplied to customers at Accentus Medical's ISO13485:2012 and ISO9001:2008 accredited facility. Accentus Medical is also very well known for the medical device testing programmes offered by its in-house test laboratories. Manufacturers have been utilising test results provided by the company for many years as part of device homologation files all over the world.

For further information, please visit: www.accentus-medical.com

About OBN

OBN is the membership organisation supporting and bringing together the UK's emerging life sciences companies, corporate partners and investors. The OBN Annual Awards celebrate outstanding achievements within the UK life sciences sector over the preceding year.